Mark J. Roschewski, MD

Experts weigh ctDNA blood tests in lymphoma, highlighting phased-variant assays for end-of-therapy sensitivity and future tech advances.

How ctDNA trends after CAR T reshape relapse monitoring, pairing MRD blood tests with PET scans to gauge response and relapse risk.

Can ctDNA and interim PET guide shorter DLBCL chemo? Experts weigh de-escalation to cut toxicity, urging randomized trials.

Can ctDNA and interim PET guide shorter DLBCL chemo? Experts weigh de-escalation to reduce toxicity and urge randomized trials.

Alpha-3 sparks debate on treating ctDNA-positive lymphoma early—can allo CAR T or bispecifics erase MRD without excess toxicity?

Can ctDNA spot relapse early and justify treating "molecular" lymphoma? Alpha-3 tests allo CAR T, weighing toxicity, MRD clearance, survival.

Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses the use of dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan; DA-EPOCH-R) in patients with Burkitt lymphoma.

Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses the treatment of Burkitt lymphoma in adult patients.

Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan; DA-EPOCH-R) in adult patients with Burkitt lymphoma.